Lipella Pharmaceuticals, Inc. · OTC:LIPO
Lipella Pharmaceuticals — Investor Presentation (January 2024)
25 slides from Lipella Pharmaceuticals's investor presentation, January 2024
Slide 1: A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need
A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need NASDAQ:LIPO lipellapharmaceuticals.com
Slide 2: Disclaimers
NASDAQ:LIPO Disclaimers The info rmatio n in this pre s entatio n is be ing pro vid e d s o yo u c an familiarize yo urs e lf with Lipella P harmac e utic als Inc . (“Lipe lla,” the “C o mpany,” “we ,” “us ,” o r “o ur”) d uring this info rmatio nal me e ting. W e re q ue s t that yo u ke e p any in
Slide 3: Mission
NASDAQ:LIPO Mission Lip e lla is c o mmitte d to p ro vid ing s up p o rtive c are to c anc e r s urvivo rs . O ur mis s io n is to d e ve lo p and c o mme rc ialize tre atme nts fo r s e rio us d is e as e s re s ulting fro m c anc e r tre atme nts inc lud ing rad iatio n and c he mo the rap y. A C
Slide 4: Business Growth Strategy
NASDAQ:LIPO Business Why rare and orphan drugs? Growth • Lipella can be first to market by pursuing conditions for which there are no current FDA approved treatments. • Requires smaller and less costly drug trials with greater flexibility from the Strategy FDA. • Orphan drug market exclusivity limit
Slide 5: About / Market Data
NASDAQ:LIPO Market Data About SYMBOL NASDAQ: LIPO Lipe lla P harmac e utic als is a c linic al- s tag e bio te c hno lo g y Price as of 1-05-2024 $1.09 c o mpany d e ve lo ping ne w d rug s 52 Week Range $0.85 - $6.10 by re f o rmulating ac tive ag e nts in e xis ting g e ne ric d rug s f o r Averag
Slide 6: Overview of Opportunity
NASDAQ:LIPO Overview of Opportunity Drug Development Drug Delivery Lead product candidate, LP - 10, a 505(b)(2) drug Proprietary drug delivery technology with candidate for hemorrhagic cystitis. potential applications in bladder, urethra, oral cavity, esophageal and colonic. LP- 10 granted FDA Orpha
Slide 7: Executive Summary
NASDAQ:LIPO Executive Summary Emerging, clinical - stage, proprietary 505(b)(2) opportunity Drug - Delivery Focused Biotech Impressive Revenue Potential O p timize d f o r 5 0 5 (b )(2) e p ithe lial tis s ue s $20,000 $1.2 billion annual revenue annual revenue P ate nte d lip o s o mal lo c al d ru
Slide 8: Cancer Survivorship and Potential Addressable Market
NASDAQ:LIPO Cancer Prostate Cancer Uterine Corpus Cancers Rectal & Other Pelvic Survivorship 700,000 1 200,000 1 300,000 1 and Potential P e lvic R ad iatio n S urvivo rs P e lvic R ad iatio n S urvivo rs P e lvic R ad iatio n S urvivo rs 42,000 2 12,000 2 18,000 2 Addressable Severe HC Survivors Se
Slide 9: Asset Pipeline
NASDAQ:LIPO Asset Pipeline A growing pipeline with strong patent protection Product Target Marketing Next Anticipated Preclinical Phase 1 Phase 2 Phase 3 Candidate Indication Approval Milestone FDA Type - C He mo rrhag ic LP- 10 mtg C o mple te d C ys titis No v. 7, 20 23 P has e - 2a IND O ral Lic
Slide 10: Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss
NASDAQ:LIPO Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss Hemorrhagic cystitis is a serious, life - threatening bladder damage from pelvic radiation therapy and/or bladder - toxic chemotherapy. Millio ns o f patie nts are 20 % o f the s e patie nts An inc re as ing US Ye ars afte r re c e iv
Slide 11: LP-10 for Hemorrhagic Cystitis
NASDAQ:LIPO LP- 10 for Hemorrhagic Cystitis Liposomal tacrolimus treatment for hemorrhagic cystitis Potent vasoconstrictor; re d uc e s c apillary blo o d f lo w to the blad d e r lume n Sterile powder Potent anti - inflammatory; inhibits c yto kine Easy to deliver c as c ad e and re d uc e s injury
Slide 12: LP-10: an Outstanding Drug Candidate
NASDAQ:LIPO LP- 10: an Outstanding Drug Candidate Multiple reasons increase LP - 10 probability of success • W e ll K no wn me c hanis m o f Well known Potential ac tio n mechanism 505(b)(2) $1.2 billion pathway Ongoing of action revenue • P re - c linic al e f f ic ac y clinical evidence • 5 0 5 (b
Slide 13: LP-10: Phase 2a Trial
NASDAQ:LIPO LP- 10: Phase 2a Trial A Phase 2a clinical trial (NCT01393223): Top line results Next Steps • All subjects tolerated LP - 10 • Type - C meeting with the FDA • Multi - center, dose - escalation instillations with no serious adverse completed Nov. 7, 2023 study events (SAE) reported • FDA
Slide 14: Bleeding: Cystoscopy & Microscopy
NASDAQ:LIPO Bleeding: Cystoscopy & Microscopy A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need 14
Slide 15: LP-10 Phase 2b Trial Design
NASDAQ:LIPO LP- 10 Phase 2b Trial Design Key criteria: R and o mize d , d o uble - blind , plac e bo c o ntro lle d , multi- c e nte r c linic al trial o f 36 Male and Fe male he mo rrhagic c ys titis patie nts , rand o mize d 1:1:1 S ubje c ts will be rand o mize d into o ne o f thre e gro ups : 2m
Slide 16: LP-310 for Oral Lichen Planus
NASDAQ:LIPO LP- 310 for Oral Lichen Planus Oral Lichen Planus (OLP) is a chronic inflammatory, T- cell - mediated autoimmune oral mucosal disease • P ainful and c o me s with the ris k o f c o mp lic atio ns inc lud ing infe c tio ns , s c arring , s tre s s and d e p re s s io n. • Has malig nant p
Slide 17: Manufacturing Capabilities
NASDAQ:LIPO Manufacturing Capabilities • Lipella maintains a sterile manufacturing facility in Pittsburgh, PA for the production of clinical supplies and research products. • LP- 10 has been produced at high quantities in this facility for Lipella's clinical trials. • The facility is also used for d
Slide 18: Experienced Management Team
NASDAQ:LIPO Experienced Management Team Lipella is led by an experienced team with complementary skillset and years of experience working together. Jonathan Kaufman, PhD Michael Chancellor, MD Chief Executive Officer Chief Medical Officer • 23 + Ye ars E xpe rie nc e • 3 0 + Ye ars E xpe rie nc e •
Slide 19: Key Takeaways
NASDAQ:LIPO Key Takeaways Drug Development Drug Delivery Lead product candidate, LP - 10, a 505(b)(2) drug candidate for Proprietary drug delivery technology with hemorrhagic cystitis. potential applications in bladder, urethra, LP- 10 granted FDA Orphan Drug Designation; potential candidate oral ca
Slide 20: A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need
A Clinical Stage Biotechnology Company Addressing Serious Diseases with NASDAQ:LIPO Significant Unmet Need Lipella Pharmaceuticals Inc. 7800 Susquehanna Street, Suite 505 Pittsburgh, PA 15208 412- 894 - 1853 lipellapharmaceuticals.com
Slide 21: LP-10 Phase 2a Trial Patient Demographics
NASDAQ:LIPO LP- 10 Phase 2a Age, years Mean 67 Comment Range 25- 89 Trial Patient Race • White 9 Demographics • Non - White 4 Radiation induced HC 11 Chemotherapy induced HC 2 Cancer • Prostate cancer 9 • Bladder cancer 2 • Lymphoma 2 Duration of HC years 4 Range 1- 14 years medication, HBO, cathete
Slide 22: LP-10 Safety
NASDAQ:LIPO Number Comment LP- 10 Safety Product related significant adverse events 0 Subject discontinuations 0 Number of subjects with adverse events 6/13 12 AEs reported in 6 subjects Adverse events (AE) 2 mg : 4 AEsin 3 subjects 4 mg: 2 AEs in 1 subject 8 mg: 6 AEs in 2 subjects Bladder spasm, u
Slide 23: Hematuria & Incontinence
NASDAQ:LIPO Hematuria & Incontinence A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need 23
Slide 24: Dose Response: Bleeding by Cystoscopy
NASDAQ:LIPO Dose Response: Bleeding by Cystoscopy A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need 24
Slide 25: Dose Response: Urinary Urge Incontinence
NASDAQ:LIPO Dose Response: Urinary Urge Incontinence A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need 25
Lipella Pharmaceuticals — Investor Presentation (January 2024) on 6ix